Loading
iRECIST is the version of the scan-measuring rules used in immunotherapy trials, where a tumour can look bigger before it shrinks, so apparent growth must be confirmed on a later scan before it counts as progression.
Tumours respond to immunotherapy differently from chemotherapy. The RECIST working group wrote iRECIST (Seymour and colleagues, Lancet Oncology 2017) as a consensus guideline for using a modified RECIST 1.1 in trials of immunotherapy, to make the design, data collection and analysis of those trials consistent and to build a data warehouse for validating it later. Responses carry an i prefix (iCR, iPR, iSD). Growth that meets RECIST 1.1 progression is recorded as unconfirmed progression (iUPD) and becomes confirmed progression (iCPD) only when the next assessment shows further growth, more new lesions, or progression in another lesion category; if the tumour shrinks instead, the bar resets. Clinical stability is considered when deciding whether to continue treatment after iUPD.
Showing the technology this term belongs to: CT (computed tomography).
Shares iRANO (immunotherapy response in neuro-oncology), RECIST, MRI.
Shares RECIST, CT (computed tomography), MRI.
Shares Progressive disease and radiographic progression, RECIST.
Shares itRECIST (response criteria for injected immunotherapy), Immune checkpoint inhibitors.
Shares RECIST, CT (computed tomography), MRI.
Shares RECIST, CT (computed tomography), MRI.
Shares iRANO (immunotherapy response in neuro-oncology), LYRIC (lymphoma response to immunomodulatory therapy criteria), Progressive disease and radiographic progression, RECIST.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/